Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

PHASE4CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
GlaucomaOcular Hypertension
Interventions
DRUG

fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution

1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (Combigan®) taken approximately 12 hours apart, up to 2 times a day and 1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken once every 24 hours.

DRUG

bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops

1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken approximately every 24 hours; mild lubricant eyedrops (Gen Teal® Mild) for masking purposes

Trial Locations (1)

Unknown

Dallas

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY